GC kinase inhibitors belong to a specific class of chemical compounds designed to target and modulate the activity of guanylate cyclase (GC) kinases. Guanylate cyclases are enzymes that play a crucial role in cellular signaling pathways by catalyzing the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). This cyclic nucleotide serves as a secondary messenger in various physiological processes, including vasodilation, neurotransmission, and smooth muscle relaxation. GC kinase inhibitors, as the name suggests, act by impeding the function of GC kinases, which are enzymes responsible for phosphorylating and activating guanylate cyclases. By inhibiting these kinases, the inhibitors disrupt the normal signaling cascade, ultimately leading to altered cellular responses.
GC kinase inhibitors is meticulously designed to interact with the catalytic domain of GC kinases, hindering their ability to phosphorylate guanylate cyclases effectively. This interaction is often achieved through the formation of reversible or irreversible bonds with specific amino acid residues within the enzyme's active site. Subsequently, the inhibition of GC kinases results in decreased cGMP production, influencing downstream cellular events. The development and refinement of GC kinase inhibitors exemplify a targeted approach to modulating intracellular signaling pathways, with potential applications in various research contexts where precise control over cyclic nucleotide signaling is essential for understanding cellular processes and regulatory mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methylene blue | 61-73-4 | sc-215381B sc-215381 sc-215381A | 25 g 100 g 500 g | $43.00 $104.00 $328.00 | 3 | |
Inhibits soluble guanylate cyclase (sGC) by competing with NO for binding to the heme moiety of the enzyme. | ||||||
5-(chloromethyl)-3-thien-2-yl-1,2,4-oxadiazole | 63417-81-2 | sc-277970 | 1 g | $128.00 | ||
Specific inhibitor of sGC, reduces cGMP synthesis by preventing its activation. | ||||||
Rp-8-Br-PET-cGMPs | 185246-32-6 | sc-215820 sc-215820A | 1 mg 5 mg | $343.00 $1348.00 | 1 | |
Inhibits cGMP-dependent protein kinase (PKG), which is downstream of sGC-cGMP signaling. | ||||||
KT5823 | 126643-37-6 | sc-3534 sc-3534A sc-3534B | 100 µg 1 mg 5 mg | $182.00 $1228.00 $4895.00 | 21 | |
Selective inhibitor of PKG, thus indirectly affecting the sGC-cGMP pathway. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
Inhibitor of nitric oxide synthase, decreasing NO levels and thereby sGC activity. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Inhibits phosphodiesterase 3 (PDE3), leading to increased cAMP levels, indirectly affecting cGMP signaling. | ||||||